Compounds for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
The present invention is directed to novel non-invasive diagnostic tools/compounds comprising a cyclic peptide wherein the compound binds to a MSH receptor to image and treat cancers, especially, melanoma, including metastatic melanoma in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probes are capable of detecting cancerous melanoma cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention will also be useful to initiate therapy for melanoma as well as monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.
- Research Organization:
- Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
- Sponsoring Organization:
- USDOE National Nuclear Security Administration (NNSA)
- DOE Contract Number:
- AC52-06NA25396
- Assignee:
- STC.UNM (Albuquerque, NM)
- Patent Number(s):
- 10,265,425
- Application Number:
- 15/186,764
- OSTI ID:
- 1568221
- Resource Relation:
- Patent File Date: 06/20/2016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Compositions for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
Human metastatic melanoma cell lines express high levels of growth hormone receptor and respond to GH treatment